


<b>INFORMATION DISCLOSURE CITATION</b> 	Docket No.: RLL-293US	Serial No.: 10/552,456
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Jason Nolan Group: Art Unit 1626

### U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JN/	A1	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
/JN/	A2	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
/JN/	A3	5,397,800	3/14/1995	Alker <i>et al.</i>	514	413	
/JN/	A4	5,559,269	9/24/1996	Johansson <i>et al.</i>	564	443	
/JN/	A5	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
/JN/	A6	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
/JN/	A7	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
/JN/	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
/JN/	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08		
/JN/	B3	EP 0 801 067	10/15/1997	EPO	C07D	453/02		
/JN/	B4	EP 0 823 423	2/11/1998	EPO	C07D	211/46		
/JN/	B5	GB 940,540	10/30/1963	UK	C07C			
/JN/	B6	JP 135958/1994	5/17/1994	Japan	C07D	333/16		
/JN/	B7	JP 92921/1994	4/5/1994	Japan	C07C	237/20		
/JN/	B8	WO 91/09013	6/27/1991	PCT	C07D	207/08		
/JN/	B9	WO 93/16018	8/19/1993	PCT	C05F	17/02		
/JN/	B10	WO 93/16048	8/19/1993	PCT	C07D	211/26		
/JN/	B11	WO 96/33973	10/31/1996	PCT	C07D	211/46		
/JN/	B12	WO 97/45414	12/4/1997	PCT	C07D	211/58		
/JN/	B13	WO 98/00016	1/8/1998	PCT	A01N	43/38		
/JN/	B14	WO 98/00109	1/8/1998	PCT	A61K	9/08		

EXAMINER	/Jason Nolan/	DATE CONSIDERED	06/17/2007
----------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<b>INFORMATION DISCLOSURE CITATION</b> 	Docket No.: RLL-293US	Serial No.: 10/552,456
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Group: Jason Nolan Art Unit 1626

/JN/	B15	WO 98/00132	1/8/1998	PCT	A61K	31/40	
/JN/	B16	WO 98/00133	1/8/1998	PCT	A61K	31/40	
/JN/	B17	WO 98/05641	2/12/1998	PCT	C07D	211/46	
/JN/	B18	WO 98/29402	7/9/1998	PCT	C07D	311/20	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

/JN/	C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)					
/JN/	C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)					
/JN/	C3	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)					
/JN/	C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)					
/JN/	C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)					
/JN/	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)					
/JN/	C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)					
/JN/	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)					
/JN/	C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282					
/JN/	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)					
/JN/	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)					
/JN/	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :984-987 (2002)					
/JN/	C13	Braish et al., "Construction of the (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996)					

EXAMINER	/Jason Nolan/	DATE CONSIDERED	06/17/2007
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

<b>INFORMATION DISCLOSURE CITATION</b> 	Docket No.: RLL-293US	Serial No.: 10/552,456
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Group: Jason Nolan Art Unit 1626

/JN/		Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
/JN/	C15	Cheng and Prusoff, "Relationship between the inhibition constant ( <i>K</i> <sub>1</sub> ) and the concentration of inhibitor which causes 50 per cent inhibition ( <i>I</i> <sub>50</sub> ) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)
/JN/	C16	Andersson et al, "Asymmetric Total Synthesis of (+)-Tolterodine, a New Muscarinic Receptor Antagonist, via Copper-Assisted Asymmetric Conjugate Addition of Aryl Gridngard Reagents to 3-Phenyl-prop-2-enoyl-oxazolidinones", <i>Journal of Organic Chemistry</i> , <u>63</u> (22): 8067-8070 (1998)

EXAMINER /Jason Nolan/	DATE CONSIDERED 06/17/2007
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	